-
公开(公告)号:US20070148170A1
公开(公告)日:2007-06-28
申请号:US11538406
申请日:2006-10-03
申请人: John Desjarlais , Sher Karki , Gregory Lazar , John Richards , Gregory Moore , David Carmichael
发明人: John Desjarlais , Sher Karki , Gregory Lazar , John Richards , Gregory Moore , David Carmichael
IPC分类号: A61K39/395 , C07K16/28
CPC分类号: C07K16/00 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K2317/41 , C07K2317/52 , C07K2317/72 , C07K2317/732 , C07K2317/77
摘要: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
-
公开(公告)号:US20070275460A1
公开(公告)日:2007-11-29
申请号:US11538411
申请日:2006-10-03
申请人: John Desjarlais , Sher Karki , Gregory Lazar , John Richards , Gregory Moore , David Carmichael
发明人: John Desjarlais , Sher Karki , Gregory Lazar , John Richards , Gregory Moore , David Carmichael
CPC分类号: C07K16/2887 , C07K2317/52 , C07K2317/732
摘要: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
摘要翻译: 本发明涉及具有优化的Fc受体结合特性的Fc变体,其产生方法,包含具有优化的Fc受体结合特性的Fc变体的Fc多肽,以及使用具有优化的Fc受体结合特性的Fc变体的方法。
-
公开(公告)号:US20140377270A1
公开(公告)日:2014-12-25
申请号:US14207489
申请日:2014-03-12
申请人: Gregory Moore , Matthew Bernett , Rumana Rashid , John Desjarlais
发明人: Gregory Moore , Matthew Bernett , Rumana Rashid , John Desjarlais
IPC分类号: C07K16/28
CPC分类号: C07K16/2803 , C07K16/2809 , C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/565 , C07K2317/62 , C07K2317/622
摘要: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
摘要翻译: 本发明涉及用于各种双特异性形式的优化的抗CD3可变序列,包括利用scFv组分的那些。 本发明还涉及编码多肽的核酸,包含其的载体和包含载体的宿主细胞。 另一方面,本发明提供包含所述多肽的药物组合物和多肽的医学用途。
-
公开(公告)号:US20060228758A1
公开(公告)日:2006-10-12
申请号:US11388570
申请日:2006-03-23
申请人: Umesh Muchhal , John Desjarlais , Gregory Moore
发明人: Umesh Muchhal , John Desjarlais , Gregory Moore
CPC分类号: G01N33/56977
摘要: Methods, apparatuses, and compounds for screening or detecting binding of candidate peptides to an MHC protein is provided. A first component including at least one candidate peptides and a second component including at least one MHC protein are contacted. One of the components is immobilized on a solid support. The presence, absence, or quantity of binding of the peptide and said MHC protein is then determined.
摘要翻译: 提供了用于筛选或检测候选肽与MHC蛋白的结合的方法,装置和化合物。 接触包含至少一种候选肽的第一组分和包含至少一种MHC蛋白的第二组分。 其中一个组分固定在固体支持物上。 然后确定肽和所述MHC蛋白的结合的存在,不存在或数量。
-
公开(公告)号:US20050181994A1
公开(公告)日:2005-08-18
申请号:US10952493
申请日:2004-10-12
IPC分类号: A61K38/00 , C07K14/525 , C07K14/705 , A61K38/17 , C07K14/74
CPC分类号: C07K14/525 , A61K38/00 , C07K14/70575 , C07K2319/00
摘要: The present invention relates to soluble, recombinant CD40L variant proteins that may be expressed solubly in E. coli. The variants of the present invention may substantially reduced binding to alpha IIb-beta3 integrin, act as CD40L antagonists or agonists, and methods for generating the same.
摘要翻译: 本发明涉及可溶于大肠杆菌中的可溶性重组CD40L变体蛋白。 本发明的变体可以显着降低与作为CD40L拮抗剂或激动剂的αIIb-β3整联蛋白的结合,以及用于产生它们的方法。
-
公开(公告)号:US20070054359A1
公开(公告)日:2007-03-08
申请号:US11421062
申请日:2006-05-30
申请人: Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
发明人: Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
IPC分类号: C07K14/475 , C07K14/52 , C12P21/06
CPC分类号: C07K14/5759
摘要: An adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin, wherein the adiponectin variant has at least one covalently attached non-peptide moiety at at least one position selected from the group consisting of: A108, Y109, S146, D179, E220, R221, and L224, relative to human adiponectin
摘要翻译: 脂联素变体与人脂联素的残基110-244相比具有至少3倍增加的溶解度,其中所述脂连蛋白变体在选自以下的至少一个位置具有至少一个共价连接的非肽部分:A108, Y109,S146,D179,E220,R221和L224相对于人脂连蛋白
-
公开(公告)号:US20060270598A1
公开(公告)日:2006-11-30
申请号:US11421060
申请日:2006-05-30
申请人: Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
发明人: Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
IPC分类号: A61K38/17
CPC分类号: A61K38/2264 , A61K31/155 , A61K38/28 , A61K2300/00
摘要: A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin
摘要翻译: 一种用脂联素介导的病症治疗哺乳动物的方法,其包括给予治疗有效量的脂联素变体,其相对于人脂连蛋白的残基110-244具有至少3倍增加的溶解度
-
公开(公告)号:US20050266464A1
公开(公告)日:2005-12-01
申请号:US11132162
申请日:2005-05-17
IPC分类号: A61K38/00 , A61K38/17 , C07H21/04 , C07K14/47 , C07K14/575 , C07K14/74 , C07K14/78 , C12N15/09 , C12P21/06 , C12Q1/68
CPC分类号: C07K14/5759 , A61K38/00 , C07K14/78
摘要: The present invention relates to non-naturally occurring variant C1q Super Family member proteins with reduced immunogenicity. More specifically, the present invention relates to variant adiponectin and CTRP1 proteins with reduced immunogenicity.
摘要翻译: 本发明涉及具有降低的免疫原性的非天然存在的C1q超级家族成员蛋白质。 更具体地,本发明涉及具有降低的免疫原性的变体脂联素和CTRP1蛋白。
-
公开(公告)号:US20050114037A1
公开(公告)日:2005-05-26
申请号:US10956352
申请日:2004-09-30
IPC分类号: C07K1/107 , C07K14/505 , C07K14/525 , C07K14/56 , C07K14/61 , G01N31/00 , G01N33/48 , G01N33/50 , G06F19/00
CPC分类号: C07K1/1077 , A61K38/00 , A61K47/60 , C07K14/505 , C07K14/525 , C07K14/535 , C07K14/565 , C07K14/61 , C07K2299/00 , C40B30/02 , G06F19/16
摘要: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
摘要翻译: 本发明涉及使用模拟技术来合理优化连接的聚合物部分的位置和大小,用于修饰治疗性蛋白质和由该方法产生的蛋白质。
-
公开(公告)号:US20150307629A1
公开(公告)日:2015-10-29
申请号:US14673695
申请日:2015-03-30
申请人: Matthew Bernett , Seung Chu , Gregory Moore , John Desjarlais
发明人: Matthew Bernett , Seung Chu , Gregory Moore , John Desjarlais
CPC分类号: C07K16/468 , C07K16/2809 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
摘要翻译: 本发明提供了包括异二聚体抗体的新型异二聚体蛋白。
-
-
-
-
-
-
-
-
-